Impact of temporary and involuntary suppression of hydroxyurea treatment on hematological and clinical parameters in patients with sickle cell disease
Authors:
- Ana Kélvia Araújo ArcanjoAAAna Kélvia Araújo Arcanjo
- Eric Arcanjo BringelEBEric Arcanjo Bringel
- José Jackson Do Nascimento CostaJCJosé Jackson Do Nascimento Costa
- Alaíde Maria Rodrigues PinheiroAPAlaíde Maria Rodrigues Pinheiro
- Antônia Moemia Lúcia Rodrigues PortelaAPAntônia Moemia Lúcia Rodrigues Portela
- Júlia Oliveria de AssisJAJúlia Oliveria de Assis
- Vicente de Paulo Teixeira PintoVPVicente de Paulo Teixeira Pinto
Open Access
- 1 January 2024
- journal article
- abstracts
- Published by Research, Society and Development in Research, Society and Development
- Vol. 13 (1)
Abstract
Objective: Here we investigate the impact of involuntary and temporary interruption of hydroxyurea (HU) treatment in patients with Sickle Cell Disease (SCD). Methods: Clinical and hematological parameters were explored in 30 patients with SCD under treatment with HU. The study was performed in two different periods: 1 - During nine months of involuntary discontinuation (April/2015 to January/2016) and 2 – During nine months after resumption of the treatment (March/2016 to December/2016). Results: The resumption of HU treatment improved the hematological parameters, by increasing levels of hemoglobin (+0.65±0.71), hematocrit (+1.16±2.26), mean corpuscular volume (+8.33±5.89), mean corpuscular hemoglobin (+3.15±2.65). There was a reduction in red blood cell distribution width (-0.66±1.69), reticulocytes (-2.53±1.96), leukocytes (-1122±2764) and platelets numbers (-79.933±162.756). These was followed by a reduction in hospital admissions (-0.30±0.79) and in the number of pain episodes (-0.97±1.19), whereas the denial in episodes of pain crisis increased (+1.43±1.43). After resumption, in period 2, hemoglobin levels were inversely correlated with blood transfusion numbers (p=0.034) and acute thoracic syndrome (p=0.017). The hematocrit was inversely correlated with the number of consultations (p=0.030) and the number of times patients denied crisis (p=0.002). Conclusions: Our study shows that the treatment with HU improves clinical and haematological parameters in patients and highlights the negative effects of the discontinuation of the treatment in the quality of life in patients with SCD.Keywords
This publication has 14 references indexed in Scilit:
- Hydroxyurea (hydroxycarbamide) for sickle cell diseaseCochrane Database of Systematic Reviews, 2022
- HYDREA E NEOPLASIA EM PACIENTES FALCIFORMEHematology, Transfusion and Cell Therapy, 2021
- Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasmsRevista Brasileira de Ginecologia e Obstetrícia, 2017
- Clinical and laboratory profile of patients with sickle cell anemiaRevista Brasileira de Ginecologia e Obstetrícia, 2017
- Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the Lessons from the Twitch Study?Blood, 2016
- Survival in adults with sickle cell disease in a high-income settingBlood, 2016
- Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocitiesBlood, 2016
- Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialThe Lancet, 2016
- Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND studyAmerican Journal of Hematology, 2015
- Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early DeathNew England Journal of Medicine, 1994